[go: up one dir, main page]

WO2000039301A3 - Methods for using mycobacterium tuberculosis molecules as immunological adjuvants - Google Patents

Methods for using mycobacterium tuberculosis molecules as immunological adjuvants Download PDF

Info

Publication number
WO2000039301A3
WO2000039301A3 PCT/US1999/030975 US9930975W WO0039301A3 WO 2000039301 A3 WO2000039301 A3 WO 2000039301A3 US 9930975 W US9930975 W US 9930975W WO 0039301 A3 WO0039301 A3 WO 0039301A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium tuberculosis
methods
immunological adjuvants
proteins
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/030975
Other languages
French (fr)
Other versions
WO2000039301A2 (en
WO2000039301A9 (en
Inventor
Yasir Skeiky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU25945/00A priority Critical patent/AU2594500A/en
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to CA002356669A priority patent/CA2356669A1/en
Priority to EP99968552A priority patent/EP1141312A2/en
Publication of WO2000039301A2 publication Critical patent/WO2000039301A2/en
Publication of WO2000039301A3 publication Critical patent/WO2000039301A3/en
Anticipated expiration legal-status Critical
Publication of WO2000039301A9 publication Critical patent/WO2000039301A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to immunological adjuvants. In particular, it relates to Mycobacterium tuberculosis proteins which stimulate interleukin-12 (IL-12) and interferon gamma production. These proteins and fragments thereof may be used in combination with an antigen for inducing and/or enhancing an immune response to the antigen. Alternatively, polynucleotides encoding such proteins may be ligated with an antigen coding sequence to produce a fusion protein as an immunogen.
PCT/US1999/030975 1998-12-24 1999-12-23 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants Ceased WO2000039301A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU25945/00A AU2594500A (en) 1998-12-24 1999-12-21 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
CA002356669A CA2356669A1 (en) 1998-12-24 1999-12-23 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
EP99968552A EP1141312A2 (en) 1998-12-24 1999-12-23 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22041698A 1998-12-24 1998-12-24
US09/220,416 1998-12-24

Publications (3)

Publication Number Publication Date
WO2000039301A2 WO2000039301A2 (en) 2000-07-06
WO2000039301A3 true WO2000039301A3 (en) 2001-05-03
WO2000039301A9 WO2000039301A9 (en) 2001-10-18

Family

ID=22823460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030975 Ceased WO2000039301A2 (en) 1998-12-24 1999-12-23 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants

Country Status (4)

Country Link
EP (1) EP1141312A2 (en)
AU (1) AU2594500A (en)
CA (1) CA2356669A1 (en)
WO (1) WO2000039301A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012467B2 (en) 2004-11-16 2011-09-06 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US10053687B2 (en) 2006-11-01 2018-08-21 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens of Mycobacterium tuberculosis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003082D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Vaccine
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
NZ519667A (en) * 2002-06-19 2005-02-25 Univ Massey A putative 23kDa lipoprotein from Mycobacterium paratuberculosis and its use in Johne's disease
DE60325586D1 (en) * 2003-08-22 2009-02-12 Axenoll Ag Mycobacterial protein antigens for cancer therapy and vaccination

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599545A (en) * 1990-05-07 1997-02-04 University College London Mycobacterium as adjuvant for antigens
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A2 (en) * 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599545A (en) * 1990-05-07 1997-02-04 University College London Mycobacterium as adjuvant for antigens
WO1997009428A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A2 (en) * 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998044119A1 (en) * 1997-04-02 1998-10-08 Statens Serum Institut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAUNOIS P ET AL: "T-CELL-EPITOPE MAPPING OF THE MAJOR SECRETED MYCOBACTERIAL ANTIGEN AG85A IN TUBERCULOSIS AND LEPROSY", INFECTION AND IMMUNITY,US,AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 62, no. 9, 1 September 1994 (1994-09-01), pages 3679 - 3687, XP000572211, ISSN: 0019-9567 *
SINHA R K ET AL: "Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 15, no. 6-7, 1 April 1997 (1997-04-01), pages 689 - 699, XP004064532, ISSN: 0264-410X *
SKEIKY ET AL: "LeIF: a recombinant Leishmania protein that induces and IL-12-mediated Th cytokine profile", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, 1998, pages 6171 - 6179, XP002103156, ISSN: 0022-1767 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012467B2 (en) 2004-11-16 2011-09-06 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US8202723B2 (en) 2004-11-16 2012-06-19 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US8609402B2 (en) 2004-11-16 2013-12-17 Aeras Global Tb Vaccine Foundation Multivalent vaccines comprising recombinant viral vectors
US10053687B2 (en) 2006-11-01 2018-08-21 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens of Mycobacterium tuberculosis

Also Published As

Publication number Publication date
WO2000039301A2 (en) 2000-07-06
EP1141312A2 (en) 2001-10-10
WO2000039301A9 (en) 2001-10-18
AU2594500A (en) 2000-07-31
CA2356669A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO1995029193A3 (en) Melanoma antigens
GB2303854B (en) Helicobacter proteins and vaccines
EP1092774A3 (en) Borrelia burgdorferi antigen OspA, gene encoding it and uses thereof
CA2190473A1 (en) Recombinant papilloma virus l1
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
EP1847549A3 (en) Papillomavirus polyprotein constructs
WO2000006737A8 (en) Streptococcus pneumoniae proteins and nucleic acid molecules
NZ508366A (en) Neisseria meningitidis antigens and compositions
WO2000039299A3 (en) Streptococcus antigens
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
WO2002005146A3 (en) Method for disigning protein libraries with altered immunogenicity
WO1997009428A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1999042588A3 (en) Group b streptococcus antigens
IL111479A0 (en) Chimeric proteins comprising borrelia polypetides and uses therefor
CA2437201A1 (en) Methods and compositions useful for stimulating an immune response
WO2000006736A3 (en) Nucleic acids and proteins from group b streptococcus
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000039301A3 (en) Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
MXPA03006218A (en) Type 2 ctokine receptor and nucleic acids encoding same.
WO2000063385A3 (en) Nucleic acid immunization
NO20005952D0 (en) Neisseria Meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
HUP9802238A2 (en) Modified polypeptides for enhanced immunogenicity
WO1996005300A3 (en) Or-1 on orphan receptor belonging to the nuclear receptor family

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2356669

Country of ref document: CA

Ref country code: CA

Ref document number: 2356669

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999968552

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999968552

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999968552

Country of ref document: EP